Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of PCI
  • All clinical trials of primary stenting
    		•  

    Zwolle 5 (Suryapranata) study, 1998

    Treatments

    Studied treatment Stent Palmaz-Schatz
    Control treatment balloon angioplasty
    Concomittant treatment Warfarin >=3 months and ticlopidine 250 mg/d for >=2 weeks in stent group only
    Treatments description
    Crossover from Balloon Angioplasty to Stenting (%) 13  
    stent type Palmaz-Schatz 

    Patients

    Patients Patients with acute myocardial infarction
    Baseline characteristics
    Age 58y 
    male (%) 84% 

    Method and design

    Randomized effectives 112 / 115 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 12 months


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Long term death

    3 / 112
         4 / 115
         classic 0,77 [0,18;3,36]

    reinfarction

    1 / 112
         5 / 115
         0,21 [0,02;1,73]

    Revascularization

    0 / 112
         8 / 115
         0,03 [0,00;1,65]

    Bleeding

    7 / 112
         3 / 115
         classic 2,40 [0,64;9,03]

    All cause death

    2 / 112
         3 / 115
         classic 0,68 [0,12;4,02]

    long term MI

    1 / 112
         10 / 115
         0,10 [0,01;0,79]

    long term revascularization

    8 / 112
         21 / 115
         0,39 [0,18;0,85]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Long term death 3 / 112 (2,7%) 4 / 115 (3,5%) 0,77 [0,18;3,36]   7028 
    reinfarction 1 / 112 (0,9%) 5 / 115 (4,3%) 0,21 [0,02;1,73]   7028 
    Revascularization 0 / 112 (0,4%) 8 / 115 (7,0%) 0,06 [0,00;1,10]   7028 
    Bleeding 7 / 112 (6,3%) 3 / 115 (2,6%) 2,40 [0,64;9,03]   7028 
    All cause death 2 / 112 (1,8%) 3 / 115 (2,6%) 0,68 [0,12;4,02]   7028 
    long term MI 1 / 112 (0,9%) 10 / 115 (8,7%) 0,10 [0,01;0,79]   7028 
    long term revascularization 8 / 112 (7,1%) 21 / 115 (18,3%) 0,39 [0,18;0,85]   7028 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 7028: Nordmann AJ, Bucher H, Hengstler P, Harr T, Young JPrimary stenting versus primary balloon angioplasty for treating acute myocardial infarction.Cochrane Database Syst Rev 2005;:CD005313

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Long term death 2,68% 3,48% -8,0‰
    reinfarction 8,93‰ 4,35% -34,5‰
    Bleeding 6,25% 2,61% 3,6%
    All cause death 1,79% 2,61% -8,2‰
    long term MI 8,93‰ 8,70% -78,0‰
    long term revascularization 7,14% 18,26% -111,2‰


    Reference(s)

    Trials register # NA
    • Suryapranata H, van 't Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction.. Circulation 1998;97:2502-5
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend